← Back to headlines
JPMorgan Initiates ResMed with 'Overweight' Rating
JPMorgan has begun coverage of ResMed (RMD) with an 'Overweight' rating and a price target of A$37.6.
19 Apr, 17:35 — 19 Apr, 17:35
Sources
Showing 1 of 1 sources
JPMorgan has begun coverage of ResMed (RMD) with an 'Overweight' rating and a price target of A$37.6.
